首页 > 最新文献

Journal of Mental Health Policy and Economics最新文献

英文 中文
Cost-Effectiveness of Digital Preventive Parent Training for Early Childhood Disruptive Behaviour. 针对幼儿破坏性行为的数字预防性家长培训的成本效益。
IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-09-01
Elisa Rissanen, Virpi Kuvaja-Köllner, Eila Kankaanpää
<p><strong>Background: </strong>Childhood disruptive behaviour disorder associates with various, also costly problems. Parent training is effective in reducing childhood disruptive behaviour. Only a few studies have evaluated the cost-effectiveness of digital parent training in reducing children's disruptive behaviour.</p><p><strong>Aims of the study: </strong>We evaluated the two-year cost-effectiveness of an Internet and telephone assisted parent training intervention called the Strongest Families Smart Website (SFSW) for prevention of children's disruptive behaviour compared to education control (EC) from the combined perspective of the health care funder and parents.</p><p><strong>Methods: </strong>This study used data from a randomized controlled trial (RCT). The trial screened a population-based sample of 4,656 four-year-olds at annual child health clinic check-ups in Finnish primary care. A total of 464 disruptively behaving children participated in the RCT; half received the SFSW and half EC. We evaluated intention-to-treat based incremental net monetary benefit with a range of willingness to pay values. Costs contained the interventions' and parents' time-use costs. The effectiveness measure was the Child Behavior Checklist (CBCL/1.5-5) externalizing score. The trial is registered at Clinicaltrials.gov (NCT01750996).</p><p><strong>Results: </strong>From the health care funder's perspective, SFSW costs per family were €1,982 and EC €661, and from the parents' perspective SFSW costs per family were €462 and EC €77. From the combined health care funder and parents' perspective, costs were €1,707 higher in the SFSW intervention than in EC. The SFSW decreased the CBCL externalizing score (1.94, SE=0.78, p=0.01) more in comparison to the EC group. In cost-effectiveness analysis using the combined perspective, the incremental net monetary benefit was zero [95% CI €-1,524 to €1,524] if the willingness to pay for one extra point of CBCL externalizing score reduced was €879. If the willingness to pay was more than €879, the average incremental net monetary benefit was positive.</p><p><strong>Discussion: </strong>The cost-effectiveness of the SFSW depends on the decision makers' willingness to pay, which is not stated for CBCL outcomes. Also, the decision maker should consider the uncertainty of cost-effectiveness estimates. The lack of other service use information and micro-costing of SFSW and EC intervention costs weakens our conclusions. However, our study had multiple strengths, such as population-based screening, high sample size, 2-year follow-up, and use of proper methods to conduct a full economic evaluation.</p><p><strong>Implications for health care provision and use: </strong>The SFSW is effective in reducing children's disruptive behaviour. Although digitally provided, the SFSW intervention included professional time and, thus, costs. The costs of intervention to the healthcare provider and time cost to families should be taken into ac
背景:儿童破坏性行为障碍会带来各种问题,而且代价高昂。家长培训能有效减少儿童的破坏性行为。只有少数研究评估了数字家长培训在减少儿童破坏性行为方面的成本效益:我们从医疗保健资助者和家长的综合角度,评估了名为 "最强家庭智能网站"(SFSW)的互联网和电话辅助家长培训干预措施与教育对照(EC)相比,在预防儿童破坏性行为方面的两年成本效益:本研究使用了一项随机对照试验(RCT)的数据。该试验在芬兰初级保健机构的年度儿童健康诊所体检中对4656名四岁儿童进行了人口抽样筛查。共有464名有破坏性行为的儿童参加了随机对照试验,其中一半接受了《自闭症儿童自理能力测试》,另一半接受了《儿童自理能力测试》。我们对基于意向治疗的增量净货币效益进行了评估,并对支付意愿值进行了调整。成本包括干预成本和家长的时间使用成本。有效性的衡量标准是儿童行为检查表(CBCL/1.5-5)的外化评分。该试验已在 Clinicaltrials.gov (NCT01750996) 上注册:从医疗资助方的角度来看,每个家庭的 SFSW 费用为 1,982 欧元和 661 欧元;从家长的角度来看,每个家庭的 SFSW 费用为 462 欧元和 77 欧元。从医护资助者和家长的综合角度来看,自力更生社工的干预成本比教委的干预成本高出 1 707 欧元。与安亲治疗组相比,自力更生和社会工作干预组降低了 CBCL 外化得分(1.94,SE=0.78,P=0.01)。在采用综合视角进行的成本效益分析中,如果愿意为 CBCL 外化评分多降低一分而支付的费用为 879 欧元,则增量净货币效益为零 [95% CI 为 1,524 欧元至 1,524 欧元]。如果支付意愿超过879欧元,则平均净货币效益增量为正:讨论:"自力更生支援计划 "的成本效益取决于决策者的支付意愿,而 CBCL 结果并没有说明决策者的支付意愿。此外,决策者还应考虑成本效益估算的不确定性。由于缺乏其他服务使用信息以及对自力更生支援服务和儿童保健干预成本的微观成本计算,我们的结论较为薄弱。不过,我们的研究也有很多优点,如基于人群的筛查、样本量大、随访 2 年以及采用适当的方法进行全面经济评估:自毁行为筛查能有效减少儿童的破坏性行为。虽然是通过数字方式提供的,但 "自力更生学习法 "的干预包括专业时间,因此也包括成本。在实施干预时,应考虑到医疗服务提供者的干预成本和家庭的时间成本。社工服务干预的成本效益取决于医疗决策者的支付意愿:投资决策应要求对干预措施进行高质量的经济评估,并为干预措施的独立评估研究提供资金支持:决策者需要对数字干预措施进行更多的经济评估。研究应使用类似的高质量方法,以便在研究之间进行比较。在研究的早期规划阶段,应咨询卫生经济学家,以确保数据的可用性和高质量的研究。
{"title":"Cost-Effectiveness of Digital Preventive Parent Training for Early Childhood Disruptive Behaviour.","authors":"Elisa Rissanen, Virpi Kuvaja-Köllner, Eila Kankaanpää","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Childhood disruptive behaviour disorder associates with various, also costly problems. Parent training is effective in reducing childhood disruptive behaviour. Only a few studies have evaluated the cost-effectiveness of digital parent training in reducing children's disruptive behaviour.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aims of the study: &lt;/strong&gt;We evaluated the two-year cost-effectiveness of an Internet and telephone assisted parent training intervention called the Strongest Families Smart Website (SFSW) for prevention of children's disruptive behaviour compared to education control (EC) from the combined perspective of the health care funder and parents.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study used data from a randomized controlled trial (RCT). The trial screened a population-based sample of 4,656 four-year-olds at annual child health clinic check-ups in Finnish primary care. A total of 464 disruptively behaving children participated in the RCT; half received the SFSW and half EC. We evaluated intention-to-treat based incremental net monetary benefit with a range of willingness to pay values. Costs contained the interventions' and parents' time-use costs. The effectiveness measure was the Child Behavior Checklist (CBCL/1.5-5) externalizing score. The trial is registered at Clinicaltrials.gov (NCT01750996).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;From the health care funder's perspective, SFSW costs per family were €1,982 and EC €661, and from the parents' perspective SFSW costs per family were €462 and EC €77. From the combined health care funder and parents' perspective, costs were €1,707 higher in the SFSW intervention than in EC. The SFSW decreased the CBCL externalizing score (1.94, SE=0.78, p=0.01) more in comparison to the EC group. In cost-effectiveness analysis using the combined perspective, the incremental net monetary benefit was zero [95% CI €-1,524 to €1,524] if the willingness to pay for one extra point of CBCL externalizing score reduced was €879. If the willingness to pay was more than €879, the average incremental net monetary benefit was positive.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;The cost-effectiveness of the SFSW depends on the decision makers' willingness to pay, which is not stated for CBCL outcomes. Also, the decision maker should consider the uncertainty of cost-effectiveness estimates. The lack of other service use information and micro-costing of SFSW and EC intervention costs weakens our conclusions. However, our study had multiple strengths, such as population-based screening, high sample size, 2-year follow-up, and use of proper methods to conduct a full economic evaluation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implications for health care provision and use: &lt;/strong&gt;The SFSW is effective in reducing children's disruptive behaviour. Although digitally provided, the SFSW intervention included professional time and, thus, costs. The costs of intervention to the healthcare provider and time cost to families should be taken into ac","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 3","pages":"85-98"},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship of Cryptocurrency Trading to Quality of Life, Sleep and Stress Levels in Academics 加密货币交易与学术界生活质量、睡眠和压力水平的关系。
IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-09-01
Mehmet Uçar, Metin Yildiz, Necmettin Çiftci, Rukuye Aylaz
<p><strong>Background: </strong>Cryptocurrency trading has become popular with a large section of society, and the number of investors is increasing daily. It is critical to address the health impacts of cryptocurrency trading. Of particular importance is the issue of how such trading affects mental health. Research should be conducted on this topic, and where necessary, national governments should develop policies to combat these effects.</p><p><strong>Aims: </strong>This study was conducted to examine the relationship of cryptocurrency trading to quality of life, sleep, and stress levels in academics.</p><p><strong>Methods: </strong>This descriptive and cross-sectional study was conducted with 437 academics working at a state university in Turkey. A Personal Information Form, the SF-12 Quality of Life Scale, the Scopa Sleep Scale, and the Perceived Stress Scale were used to collect data. These data were analyzed using SPSS 25.0 and G*Power 3.1 programs.</p><p><strong>Results: </strong>The data obtained in this study were analyzed using SPSS program (SPSS-25). The effect size and r-effect size were calculated with Cohen’s d value. It was found that the mean scores for the SF-12 Quality of Life Scale were statistically lower in academics who traded cryptocurrency than in those who did not. The results showed that the mean scores for the Scopa Sleep Scale and Perceived Stress Scale were statistically higher in academics who traded cryptocurrency than in those who did not (p<0.05).</p><p><strong>Discussion: </strong>The academics who traded cryptocurrency had more negative health outcomes when compared to those who did not. Social awareness should be raised on the negative effects of cryptocurrency trading. A limitation of the study is that only data obtained from the statements of the participants were included in the study. The study may have some generalizability to other academics, but has less generalizability to populations other than academics.</p><p><strong>Implications for health care provision and use: </strong>Cryptocurrency trading is a significant public health problem. Although cryptocurrency trading has been found to profoundly affect mental health (sleep, stress, and quality of life), the current policies that address these problems are generally inadequate in terms of implementing and sustaining mental healthcare systems. The limitations of these health policies prevent many individuals in society from receiving high quality services.</p><p><strong>Implications for health policies: </strong>Health systems alone cannot solve the systemic problems that lead to the population’s dependence of mental health services and institutions. In order to solve this basic problem, it may be necessary for governments to increase individuals’ basic incomes and develop specific mental health policies for people engaged in cryptocurrency trading.</p><p><strong>Implications for further research: </strong>Future studies should examine expert perspectiv
背景:围产期情绪和焦虑症(PMADs)的经济成本很高,其中包括减少的成本。 背景:加密货币交易已受到社会上很大一部分人的欢迎,投资者的数量每天都在增加。解决加密货币交易对健康的影响至关重要。尤其重要的是,这种交易如何影响心理健康。本研究旨在探讨加密货币交易与学者的生活质量、睡眠和压力水平之间的关系:这项描述性横断面研究的对象是在土耳其一所国立大学工作的 437 名学者。研究使用个人信息表、SF-12 生活质量量表、Scopa 睡眠量表和感知压力量表收集数据。这些数据使用 SPSS 25.0 和 G*Power 3.1 程序进行分析:本研究获得的数据使用 SPSS 程序(SPSS-25)进行分析。用 Cohen's d 值计算了效应大小和 r-效应大小。结果发现,SF-12 生活质量量表的平均得分在统计学上,交易加密货币的学者低于不交易加密货币的学者。结果显示,在统计学上,交易加密货币的学者的 Scopa 睡眠量表和感知压力量表的平均得分高于没有交易加密货币的学者(p 讨论:与没有进行加密货币交易的学者相比,进行加密货币交易的学者对健康的负面影响更大。应提高社会对加密货币交易负面影响的认识。这项研究的局限性在于,研究中只包含了从参与者的陈述中获得的数据。这项研究可能对其他学者有一定的普适性,但对学者以外人群的普适性较差:加密货币交易是一个重大的公共卫生问题。尽管加密货币交易被发现会严重影响心理健康(睡眠、压力和生活质量),但目前解决这些问题的政策在实施和维持心理保健系统方面普遍不足。这些医疗政策的局限性使得社会上许多人无法获得高质量的服务:单靠医疗系统无法解决导致人们依赖精神医疗服务和机构的系统性问题。为了解决这一基本问题,政府可能有必要增加个人的基本收入,并为从事加密货币交易的人制定专门的心理健康政策:未来的研究应考察专家对不同背景下心理健康服务的看法(如行为成瘾服务),收集有针对性的反馈意见,并探讨战略规划和资金稳定性等问题。应就行为成瘾治疗的实施和维持做出有效决策。
{"title":"Relationship of Cryptocurrency Trading to Quality of Life, Sleep and Stress Levels in Academics","authors":"Mehmet Uçar, Metin Yildiz, Necmettin Çiftci, Rukuye Aylaz","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cryptocurrency trading has become popular with a large section of society, and the number of investors is increasing daily. It is critical to address the health impacts of cryptocurrency trading. Of particular importance is the issue of how such trading affects mental health. Research should be conducted on this topic, and where necessary, national governments should develop policies to combat these effects.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aims: &lt;/strong&gt;This study was conducted to examine the relationship of cryptocurrency trading to quality of life, sleep, and stress levels in academics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This descriptive and cross-sectional study was conducted with 437 academics working at a state university in Turkey. A Personal Information Form, the SF-12 Quality of Life Scale, the Scopa Sleep Scale, and the Perceived Stress Scale were used to collect data. These data were analyzed using SPSS 25.0 and G*Power 3.1 programs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The data obtained in this study were analyzed using SPSS program (SPSS-25). The effect size and r-effect size were calculated with Cohen’s d value. It was found that the mean scores for the SF-12 Quality of Life Scale were statistically lower in academics who traded cryptocurrency than in those who did not. The results showed that the mean scores for the Scopa Sleep Scale and Perceived Stress Scale were statistically higher in academics who traded cryptocurrency than in those who did not (p&lt;0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;The academics who traded cryptocurrency had more negative health outcomes when compared to those who did not. Social awareness should be raised on the negative effects of cryptocurrency trading. A limitation of the study is that only data obtained from the statements of the participants were included in the study. The study may have some generalizability to other academics, but has less generalizability to populations other than academics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implications for health care provision and use: &lt;/strong&gt;Cryptocurrency trading is a significant public health problem. Although cryptocurrency trading has been found to profoundly affect mental health (sleep, stress, and quality of life), the current policies that address these problems are generally inadequate in terms of implementing and sustaining mental healthcare systems. The limitations of these health policies prevent many individuals in society from receiving high quality services.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implications for health policies: &lt;/strong&gt;Health systems alone cannot solve the systemic problems that lead to the population’s dependence of mental health services and institutions. In order to solve this basic problem, it may be necessary for governments to increase individuals’ basic incomes and develop specific mental health policies for people engaged in cryptocurrency trading.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implications for further research: &lt;/strong&gt;Future studies should examine expert perspectiv","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 3","pages":"63-70"},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mental Health Expenditure in Canada. 加拿大心理健康支出。
IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-09-01
Olga Milliken, Hui Wang, Marie-Chantal Benda, Thy Dinh, Alan Diener
<p><strong>Background: </strong>Mental ill-health-illness or conditions related to mental health, including dementia, schizophrenia, mood (affective) disorders, and mental and behaviour disorders due to psychoactive substance and alcohol use - places a significant burden on society in terms of economic, health, and social costs. Focusing on direct health care costs, estimated expenditures on treating mental health conditions accounted for up to 14% of total health expenditures across 12 OECD countries over the period of 2003 to 2010.</p><p><strong>Aims of the study: </strong>The purpose of this study was to estimate the direct health care costs associated with the treatment of mental ill-health in Canada for the year 2019 using currently available guidelines. A consistent and systematic method, such as that used in the OECD guidelines on expenditure by disease, age and gender under the System of Health Accounts, can provide valuable information for policy makers and improve comparability of Canadian estimates with those of peer countries.</p><p><strong>Methods: </strong>To derive comprehensive, and internationally comparable estimates of mental health care expenditures, the results were classified according to the OECD System of Health Accounts 2011 for the following cost components: hospitals, physicians, psychologists in private practice, prescription drugs, and community mental health care. Based on data availability, both public and private expenditures were captured. Where data were lacking, estimates were based on the published literature.</p><p><strong>Results: </strong>Total expenditure for mental health care was estimated at $17.1 billion in Canada in 2019. Hospital services (inpatient and outpatient) represent the largest component totaling $5.5 billion or 32% of total mental health spending. They are followed by expenditures on prescribed pharmaceutical drugs of $4.3 billion (25%), community-based care of $3.6 billion (21%), physician services of $2.7 billion (16%) and services of psychologists in private practice of $1.1 billion (6%).</p><p><strong>Discussion: </strong>The study provided the most recent and comprehensive estimate of mental health expenditure in Canada. The results for similar cost components, are comparable to those found in the previous studies. Expenditures directed towards mental health treatment accounted for 6.4% of total health expenditures, and 6.9% of public health expenditures, in 2019, on par with the OECD average of 6.7% for twenty-three countries. Among considered cost components, community-based mental health and addiction services remain an area where further work is needed the most, including a standardized list of services reported by each Canadian province/territory regardless of care setting, service administrator or funder.  In Canada, data challenges are considerable to assess private spending out-of-pocket or through third-party insurance for services by psychologists or psychotherapists, as well
背景:精神疾病--与精神健康有关的疾病或病症,包括痴呆症、精神分裂症、情绪(情感)障碍以及因使用精神活性物质和酗酒而导致的精神和行为障碍--在经济、健康和社会成本方面给社会造成了巨大负担。以直接医疗成本为重点,2003 年至 2010 年间,在 12 个经合组织国家中,用于治疗精神疾病的估计支出占医疗总支出的 14%:本研究的目的是利用现有指南估算 2019 年加拿大与治疗精神疾病相关的直接医疗成本。经合组织(OECD)健康账户体系中按疾病、年龄和性别划分的支出指南所使用的方法等一致而系统的方法可为政策制定者提供有价值的信息,并提高加拿大的估算值与同类国家的估算值之间的可比性:为了得出全面的、具有国际可比性的精神卫生保健支出估算值,我们根据 2011 年经合组织健康账户体系对以下成本构成进行了分类:医院、医生、私人执业的心理学家、处方药和社区精神卫生保健。根据数据的可用性,公共和私人支出均被纳入其中。在缺乏数据的情况下,则根据已发表的文献进行估算:据估计,2019 年加拿大精神卫生保健的总支出为 171 亿加元。医院服务(住院病人和门诊病人)是最大的组成部分,总支出达 55 亿美元,占精神健康总支出的 32%。其次是处方药支出 43 亿加元(占 25%)、社区护理支出 36 亿加元(占 21%)、医生服务支出 27 亿加元(占 16%)和私人执业心理学家服务支出 11 亿加元(占 6%):讨论:这项研究提供了加拿大最新、最全面的心理健康支出估算。类似成本构成的结果与之前的研究结果相当。2019年,用于精神健康治疗的支出占卫生总支出的6.4%,占公共卫生支出的6.9%,与经合组织23个国家6.7%的平均水平相当。在已考虑的成本构成中,基于社区的精神健康和成瘾服务仍是最需要进一步开展工作的领域,包括加拿大各省/地区报告的标准化服务清单,而不论护理环境、服务管理者或资助者如何。 在加拿大,要评估私人自付或通过第三方保险获得心理学家或心理治疗师服务以及住宿和家庭护理的支出,数据方面的挑战相当大。鉴于数据方面的挑战,总支出估算可能比较保守。 影响:像这样具有一致性和可比性的估算可以用来更好地了解资源在心理健康治疗中的使用情况,包括主要的成本动因和政策变化的影响,以及进行可靠的辖区间和国际比较。
{"title":"Mental Health Expenditure in Canada.","authors":"Olga Milliken, Hui Wang, Marie-Chantal Benda, Thy Dinh, Alan Diener","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Mental ill-health-illness or conditions related to mental health, including dementia, schizophrenia, mood (affective) disorders, and mental and behaviour disorders due to psychoactive substance and alcohol use - places a significant burden on society in terms of economic, health, and social costs. Focusing on direct health care costs, estimated expenditures on treating mental health conditions accounted for up to 14% of total health expenditures across 12 OECD countries over the period of 2003 to 2010.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aims of the study: &lt;/strong&gt;The purpose of this study was to estimate the direct health care costs associated with the treatment of mental ill-health in Canada for the year 2019 using currently available guidelines. A consistent and systematic method, such as that used in the OECD guidelines on expenditure by disease, age and gender under the System of Health Accounts, can provide valuable information for policy makers and improve comparability of Canadian estimates with those of peer countries.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;To derive comprehensive, and internationally comparable estimates of mental health care expenditures, the results were classified according to the OECD System of Health Accounts 2011 for the following cost components: hospitals, physicians, psychologists in private practice, prescription drugs, and community mental health care. Based on data availability, both public and private expenditures were captured. Where data were lacking, estimates were based on the published literature.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Total expenditure for mental health care was estimated at $17.1 billion in Canada in 2019. Hospital services (inpatient and outpatient) represent the largest component totaling $5.5 billion or 32% of total mental health spending. They are followed by expenditures on prescribed pharmaceutical drugs of $4.3 billion (25%), community-based care of $3.6 billion (21%), physician services of $2.7 billion (16%) and services of psychologists in private practice of $1.1 billion (6%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;The study provided the most recent and comprehensive estimate of mental health expenditure in Canada. The results for similar cost components, are comparable to those found in the previous studies. Expenditures directed towards mental health treatment accounted for 6.4% of total health expenditures, and 6.9% of public health expenditures, in 2019, on par with the OECD average of 6.7% for twenty-three countries. Among considered cost components, community-based mental health and addiction services remain an area where further work is needed the most, including a standardized list of services reported by each Canadian province/territory regardless of care setting, service administrator or funder.  In Canada, data challenges are considerable to assess private spending out-of-pocket or through third-party insurance for services by psychologists or psychotherapists, as well ","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 3","pages":"75-84"},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maternal Depression and Physical Health of Under-Five Children in Turkey. 土耳其五岁以下儿童的母亲抑郁症和身体健康。
IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-06-01
Gokben Aydilek, Deniz Karaoğlan

Background: Maternal depression is the most prevalent mental health problem worldwide, especially in low- and middle-income countries. It impairs the cognitive, physical, and social abilities of mothers and disturbs effective parenting practices. Therefore, the consequences of mental, physical, and social suffering are not limited to the mother herself but are transmitted to future generations by negatively affecting the child's health.

Aim of the study: This study aims to analyse the relationship between maternal depression and child's physical health in Turkey, a middle-income, developing country.

Methods: By using the 2019 round of the "Turkish Health Survey" dataset prepared by the Turkish Statistical Institute (TurkStat), we focus on the general health status, anaemia prevalence, morbidity of acute respiratory infections (ARI) and diarrhoea along with other common short-term childhood illnesses among under-five children. Maternal depression is assessed by the standardised eight-item version of the Patient Health Questionnaire (PHQ-8). We employ a linear probability model to examine the relationship between maternal depression and the physical health of under-five children. In addition, we investigate the potential protective role of maternal education against the detrimental effects of maternal depression on child health. Since we are simultaneously analysing several outcome measures, in order to avoid any Type I error, we use the novel Romano-Wolf multiple hypothesis testing method.

Results: We find that children whose mothers suffer from mild to severe depression are at a 12 percentage points higher risk of contracting infectious diseases. Similarly, the total number of non-chronic illnesses a child falls victim to increases by one-third if the mother portrays depressive symptoms. In addition, our results suggest that completing at least high school reduces the burdens of maternal depression on children's physical health by 8 percentage points.

Discussion: Considering both the individual and societal burden of infectious disease prevalence, we conclude that the development of worldwide policies and initiatives aimed at decreasing maternal depression as much as increasing maternal education is essential for safeguarding the rights of both women and children, especially in developing countries.

Limitations of the study: The findings of this research provide a linear association between maternal mental health and under-five child's physical health, rather than a causal effect.

背景:产妇抑郁症是全球最普遍的心理健康问题,尤其是在中低收入国家。它损害了母亲的认知、身体和社交能力,干扰了有效的养育行为。因此,精神、身体和社会痛苦的后果不仅限于母亲本人,还会通过对孩子健康的负面影响传给后代:本研究旨在分析中等收入发展中国家土耳其的产妇抑郁与儿童身体健康之间的关系:通过使用土耳其统计研究所(TurkStat)编制的 2019 年 "土耳其健康调查 "数据集,我们重点研究了五岁以下儿童的总体健康状况、贫血患病率、急性呼吸道感染(ARI)和腹泻发病率以及其他常见的短期儿童疾病。孕产妇抑郁症通过标准化的八项患者健康问卷(PHQ-8)进行评估。我们采用线性概率模型来研究母亲抑郁与五岁以下儿童身体健康之间的关系。此外,我们还研究了产妇教育对产妇抑郁对儿童健康的不利影响的潜在保护作用。由于我们同时对多个结果指标进行分析,为了避免出现 I 类错误,我们采用了新颖的 Romano-Wolf 多重假设检验方法:我们发现,母亲患有轻度至重度抑郁症的儿童感染传染病的风险要高出 12 个百分点。同样,如果母亲有抑郁症状,孩子患非慢性疾病的总数会增加三分之一。此外,我们的研究结果表明,至少完成高中学业可将母亲抑郁对儿童身体健康造成的负担降低 8 个百分点:讨论:考虑到传染病流行对个人和社会造成的负担,我们得出结论,制定旨在减少孕产妇抑郁症和提高孕产妇教育水平的全球性政策和倡议,对于保障妇女和儿童的权利至关重要,尤其是在发展中国家:本研究的结果提供了产妇心理健康与五岁以下儿童身体健康之间的线性关系,而不是因果关系。
{"title":"Maternal Depression and Physical Health of Under-Five Children in Turkey.","authors":"Gokben Aydilek, Deniz Karaoğlan","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Maternal depression is the most prevalent mental health problem worldwide, especially in low- and middle-income countries. It impairs the cognitive, physical, and social abilities of mothers and disturbs effective parenting practices. Therefore, the consequences of mental, physical, and social suffering are not limited to the mother herself but are transmitted to future generations by negatively affecting the child's health.</p><p><strong>Aim of the study: </strong>This study aims to analyse the relationship between maternal depression and child's physical health in Turkey, a middle-income, developing country.</p><p><strong>Methods: </strong>By using the 2019 round of the \"Turkish Health Survey\" dataset prepared by the Turkish Statistical Institute (TurkStat), we focus on the general health status, anaemia prevalence, morbidity of acute respiratory infections (ARI) and diarrhoea along with other common short-term childhood illnesses among under-five children. Maternal depression is assessed by the standardised eight-item version of the Patient Health Questionnaire (PHQ-8). We employ a linear probability model to examine the relationship between maternal depression and the physical health of under-five children. In addition, we investigate the potential protective role of maternal education against the detrimental effects of maternal depression on child health. Since we are simultaneously analysing several outcome measures, in order to avoid any Type I error, we use the novel Romano-Wolf multiple hypothesis testing method.</p><p><strong>Results: </strong>We find that children whose mothers suffer from mild to severe depression are at a 12 percentage points higher risk of contracting infectious diseases. Similarly, the total number of non-chronic illnesses a child falls victim to increases by one-third if the mother portrays depressive symptoms. In addition, our results suggest that completing at least high school reduces the burdens of maternal depression on children's physical health by 8 percentage points.</p><p><strong>Discussion: </strong>Considering both the individual and societal burden of infectious disease prevalence, we conclude that the development of worldwide policies and initiatives aimed at decreasing maternal depression as much as increasing maternal education is essential for safeguarding the rights of both women and children, especially in developing countries.</p><p><strong>Limitations of the study: </strong>The findings of this research provide a linear association between maternal mental health and under-five child's physical health, rather than a causal effect.</p>","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 2","pages":"47-58"},"PeriodicalIF":1.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PERSPECTIVE: Implications of Recent Health Policies for Women's Reproductive Mental Health. PERSPECTIVE: Implications of Recent Health Policies for Women's Reproductive Mental Health.
IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-06-01
Kara Zivin, Anna Courant

Background: The economic cost of perinatal mood and anxiety disorders (PMADs) is high and includes the cost of reduced maternal economic productivity, more preterm births, and increases in other maternal mental health expenditures. PMADs also substantially contribute the cost of maternal morbidity. This paper offers a discussion of the quality-of-care cascade model of PMADs, which outlines care pathways that people typically face as well as gaps and unmet needs that frequently happen along the way. The model uses the US health system as an example. A discussion of international implications follows.

Discussion: The quality-of-care cascade model outlines downward dips in quality of care along the perinatal mental health treatment continuum, including access (many Americans do not have access to affordable health insurance), enrollment (even when individuals are offered health insurance, some do not enroll), coverage (even if individuals have health insurance, some needed services or providers may not be covered), choice (even if services and providers are covered, patients may not be able to choose among plans, institutions, or clinicians), consistency (even if patients have a choice of plan or provider, a consistent source of care may not be accessible), referral (even if care is available and accessible, referral services may not be), quality (even if patients have access to both care and referral services, there may be gaps in the quality of care provided), adherence (even if patients receive high-quality care, they may not be adherent to treatment), barriers (societal forces that may influence people's choices and behaviors), and shocks (unanticipated events that could disrupt care pathways). In describing the quality-of-care cascade model, this paper uses the US healthcare system as the primary example. However, the model can extend to examine quality-of-care dips along the perinatal mental health treatment continuum within the international context. Although the US healthcare system may differ from other healthcare systems in many respects, shared commonalities lead to quality-of-care dips in countries with healthcare systems structured differently than in the US.

Implications for health policies: The global cost of PMADs remains substantial, and addressing the costs of these conditions could have a significant impact on overall cost and quality of care internationally. The quality-of-care cascade model presented in this paper could help identify, understand, and address the complex contributing factors that lead to dips in quality-of-care for perinatal mental health conditions across the world.

背景:围产期情绪和焦虑障碍(PMADs)的经济成本很高,包括降低产妇的经济生产力、增加早产以及增加其他产妇心理健康支出。此外,情绪和焦虑障碍还大大增加了孕产妇的发病率。本文讨论了 PMADs 的护理质量级联模型,该模型概述了人们通常面临的护理路径,以及在此过程中经常出现的差距和未满足的需求。该模型以美国医疗系统为例。随后讨论了其国际影响:护理质量级联模型概述了围产期心理健康治疗过程中护理质量的下降,包括获取(许多美 国人无法获得负担得起的医疗保险)、注册(即使个人获得了医疗保险,有些人也没有注册)、 覆盖(即使个人拥有医疗保险,有些所需的服务或医疗服务提供者也可能不在覆盖范围内)、选 择(即使服务和医疗服务提供者在覆盖范围内,患者也可能无法在各种计划、机构或临床医生中 进行选择)、一致性(即使患者可以选择计划或医疗服务提供者,也可能无法获得一致的医疗服务)、转诊(即使可以获得医疗服务,也可能无法获得转诊服务)、质量(即使患者可以获得医疗服务和转诊服务、即使患者可以获得医疗服务和转介服务,但所提供的医疗服务质量可能存在差距)、坚持治疗(即使患者接受了高质量的医疗服务,他们也可能不坚持治疗)、障碍(可能影响人们的选择和行为的社会力量)和冲击(可能扰乱医疗路径的意外事件)。在描述护理质量级联模型时,本文以美国医疗保健系统为例。然而,该模型也可以扩展到国际范围内,用于考察围产期精神健康治疗连续体的护理质量下降情况。尽管美国的医疗保健体系在许多方面可能与其他医疗保健体系不同,但在医疗保健体系结构与美国不同的国家,共同的共性也会导致护理质量的下降:PMADs 的全球成本仍然很高,解决这些疾病的成本问题可能会对国际上的总体成本和医疗质量产生重大影响。本文介绍的护理质量级联模型有助于识别、理解和解决导致全球围产期精神疾病护理质量下降的复杂因素。
{"title":"PERSPECTIVE: Implications of Recent Health Policies for Women's Reproductive Mental Health.","authors":"Kara Zivin, Anna Courant","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The economic cost of perinatal mood and anxiety disorders (PMADs) is high and includes the cost of reduced maternal economic productivity, more preterm births, and increases in other maternal mental health expenditures. PMADs also substantially contribute the cost of maternal morbidity. This paper offers a discussion of the quality-of-care cascade model of PMADs, which outlines care pathways that people typically face as well as gaps and unmet needs that frequently happen along the way. The model uses the US health system as an example. A discussion of international implications follows.</p><p><strong>Discussion: </strong>The quality-of-care cascade model outlines downward dips in quality of care along the perinatal mental health treatment continuum, including access (many Americans do not have access to affordable health insurance), enrollment (even when individuals are offered health insurance, some do not enroll), coverage (even if individuals have health insurance, some needed services or providers may not be covered), choice (even if services and providers are covered, patients may not be able to choose among plans, institutions, or clinicians), consistency (even if patients have a choice of plan or provider, a consistent source of care may not be accessible), referral (even if care is available and accessible, referral services may not be), quality (even if patients have access to both care and referral services, there may be gaps in the quality of care provided), adherence (even if patients receive high-quality care, they may not be adherent to treatment), barriers (societal forces that may influence people's choices and behaviors), and shocks (unanticipated events that could disrupt care pathways). In describing the quality-of-care cascade model, this paper uses the US healthcare system as the primary example. However, the model can extend to examine quality-of-care dips along the perinatal mental health treatment continuum within the international context. Although the US healthcare system may differ from other healthcare systems in many respects, shared commonalities lead to quality-of-care dips in countries with healthcare systems structured differently than in the US.</p><p><strong>Implications for health policies: </strong>The global cost of PMADs remains substantial, and addressing the costs of these conditions could have a significant impact on overall cost and quality of care internationally. The quality-of-care cascade model presented in this paper could help identify, understand, and address the complex contributing factors that lead to dips in quality-of-care for perinatal mental health conditions across the world.</p>","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 2","pages":"63-70"},"PeriodicalIF":1.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PERSPECTIVE: A Fireside Chat about Global Mental Health with Dr. Esther Duflo, Nobel Laureate in Economics. 观点:与诺贝尔经济学奖获得者埃斯特-杜弗洛博士就全球心理健康问题进行炉边谈话。
IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-06-01
Benjamin Lê Cook, Esther Duflo

Dr. Esther Duflo, Nobel Laureate in Economics, and co-founder and co-director of the Abdul Latif Jameel Poverty Action Lab (J-PAL) sat down with Dr. Benjamin Cook for a "fireside chat" at the 12th National Institute of Mental Health Global Mental Health Research Without Borders Conference. Dr. Duflo discussed J-PAL's efforts to develop and test interventions for improving mental health and how cash transfer programs can be used to improve mental health. She also discussed the importance of using randomized control trials (RCTs) in shaping global mental health initiatives. Dr. Duflo shared insights from projects addressing loneliness among older individuals in India, secondary school scholarships in Ghana, and other studies that have informed social policies. Looking forward, she discusses climate change as a threat to the reductions in poverty realized in the last 30 years and encourages the expansion of networks of research and policy collaborations to improve global health.

诺贝尔经济学奖获得者、阿卜杜勒-拉蒂夫-贾米尔扶贫行动实验室(J-PAL)联合创始人兼联合主任埃斯特-杜弗洛博士与本杰明-库克博士在第 12 届美国国家心理健康研究所全球心理健康无国界研究大会上进行了一次 "炉边谈话"。Duflo 博士讨论了 J-PAL 在开发和测试改善心理健康的干预措施方面所做的努力,以及如何利用现金转移项目来改善心理健康。她还讨论了利用随机对照试验(RCT)来制定全球心理健康计划的重要性。Duflo 博士分享了印度解决老年人孤独问题的项目、加纳中学奖学金以及其他为社会政策提供信息的研究的见解。展望未来,她认为气候变化对过去30年实现的减贫目标构成威胁,并鼓励扩大研究和政策合作网络,以改善全球健康状况。
{"title":"PERSPECTIVE: A Fireside Chat about Global Mental Health with Dr. Esther Duflo, Nobel Laureate in Economics.","authors":"Benjamin Lê Cook, Esther Duflo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Dr. Esther Duflo, Nobel Laureate in Economics, and co-founder and co-director of the Abdul Latif Jameel Poverty Action Lab (J-PAL) sat down with Dr. Benjamin Cook for a \"fireside chat\" at the 12th National Institute of Mental Health Global Mental Health Research Without Borders Conference. Dr. Duflo discussed J-PAL's efforts to develop and test interventions for improving mental health and how cash transfer programs can be used to improve mental health. She also discussed the importance of using randomized control trials (RCTs) in shaping global mental health initiatives. Dr. Duflo shared insights from projects addressing loneliness among older individuals in India, secondary school scholarships in Ghana, and other studies that have informed social policies. Looking forward, she discusses climate change as a threat to the reductions in poverty realized in the last 30 years and encourages the expansion of networks of research and policy collaborations to improve global health.</p>","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 2","pages":"59-62"},"PeriodicalIF":1.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PERSPECTIVE: Health Economic Interests at NIMH and NIDA to Improve Delivery of Behavioral Health Services. PERSPECTIVE: NIMH 和 NIDA 的健康经济利益,以改善行为健康服务的提供。
IF 1 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-03-01
Jennifer L Humensky, Sarah Q Duffy, Leonardo Cubillos, Michael C Freed, Agnes Rupp
<p><strong>Background: </strong>Effective financing mechanisms are essential to ensuring that people can access and utilize effective treatments and services. Financing mechanisms are needed not only to pay for the delivery of those treatments and services, but also ancillary costs, while also keeping care affordable.</p><p><strong>Aims: </strong>This article highlights key areas of the interest of the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA) in supporting applied health economics and health care financing research. Specifically, this article discusses the long-range impact of NIH's earlier investments in applied health economics research, and NIH's ongoing efforts to communicate its interests in health economics research. We discuss the 2023 NIMH-NIDA-sponsored health economics conference, and the ideas presented there for developing and assessing innovative behavioral health care financing models; three of the presented papers were recently published in the Journal of Mental Health Policy and Economics.</p><p><strong>Methods: </strong>We describe the history and impact of NIMH- and NIDA-sponsored economic research and identify current research interests as identified in the NIMH and NIDA Strategic Plans and recent funding announcements. We examine themes presented at the NIMH-NIDA Health Economics conference. The conference included over 300 participants from 20 countries, from six continents.</p><p><strong>Results: </strong>The topics highlighted at the conference highlight the ways in which NIH-funded research has promoted the development of innovative health care financing methods, both from the supply side (e.g., providers and payers) and demand side (e.g., service users and families). Invited speakers discussed the findings from NIH-supported research in the topic areas of payment and financing, behavioral economics and social determinants of health. Keynote speakers highlighted emerging topics in the field, including the economics of health equity, biases in mental health models in health care, and value-based insurance design.</p><p><strong>Discussion: </strong>We demonstrate a resurgence of and explicit interest in health economics and policy research at NIMH and NIDA. However, more work is needed in order to design funding mechanisms that fully provide access to and facilitate use of effective evidence-based practices to improve mental health outcomes. For example, it is important that policy and health economic research projects include decision makers who will be the end users of data and study results, to ensure that results can be meaningfully put into practice.</p><p><strong>Implications for health care: </strong>Designing effective and efficient funding mechanisms can help ensure that service users have access to effective treatments and that clinicians and provider organizations are adequately compensated for their work.</p><p><strong>Implications for health policies: </strong>Fe
背景:有效的融资机制对于确保人们能够获得和利用有效的治疗和服务至关重要。目的:本文重点介绍了美国国立精神卫生研究所(NIMH)和美国国立药物滥用研究所(NIDA)在支持应用卫生经济学和医疗融资研究方面的主要关注领域。具体而言,本文讨论了美国国立卫生研究院早期对应用卫生经济学研究的投资所产生的长远影响,以及美国国立卫生研究院为宣传其对卫生经济学研究的兴趣而正在进行的努力。我们讨论了由 NIMH-NIDA 赞助的 2023 年健康经济学会议,以及会议上提出的开发和评估创新行为医疗融资模式的观点;其中三篇论文最近发表在《心理健康政策与经济学杂志》上:我们介绍了由 NIMH 和 NIDA 赞助的经济学研究的历史和影响,并确定了 NIMH 和 NIDA 战略计划中确定的当前研究兴趣以及最近的资助公告。我们研究了在 NIMH-NIDA 健康经济学会议上提出的主题。来自六大洲 20 个国家的 300 多人参加了此次会议:会议强调的主题突出了由美国国立卫生研究院资助的研究如何从供应方(如提供者和支付者)和需求方(如服务使用者和家庭)两方面促进创新医疗融资方法的发展。特邀发言人讨论了美国国立卫生研究院支持的支付与融资、行为经济学和健康的社会决定因素等主题领域的研究成果。主旨发言人重点介绍了该领域的新兴课题,包括健康公平经济学、医疗保健中心理健康模式的偏差以及基于价值的保险设计:我们表明,NIMH 和 NIDA 对卫生经济学和政策研究重新产生了明确的兴趣。然而,还需要做更多的工作,才能设计出能够充分提供和促进使用有效循证实践的资助机制,从而改善心理健康结果。例如,政策和卫生经济研究项目必须包括决策者,他们将是数据和研究结果的最终用户,以确保研究结果能被有意义地付诸实践:设计有效和高效的资助机制有助于确保服务使用者获得有效的治疗,并确保临床医生和医疗机构的工作得到充分的补偿:对卫生政策的影响:联邦、州和地方政策,以及付款人和医疗机构的政策,都会影响支持和激励的医疗类型:正如其各自的战略计划和资助公告中所概述的研究兴趣所表明的那样,NIMH 和 NIDA 将继续资助卫生经济和政策研究,旨在改善美国和全世界行为健康状况患者或有患病风险的人的医疗服务获取、质量和结果。
{"title":"PERSPECTIVE: Health Economic Interests at NIMH and NIDA to Improve Delivery of Behavioral Health Services.","authors":"Jennifer L Humensky, Sarah Q Duffy, Leonardo Cubillos, Michael C Freed, Agnes Rupp","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Effective financing mechanisms are essential to ensuring that people can access and utilize effective treatments and services. Financing mechanisms are needed not only to pay for the delivery of those treatments and services, but also ancillary costs, while also keeping care affordable.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aims: &lt;/strong&gt;This article highlights key areas of the interest of the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA) in supporting applied health economics and health care financing research. Specifically, this article discusses the long-range impact of NIH's earlier investments in applied health economics research, and NIH's ongoing efforts to communicate its interests in health economics research. We discuss the 2023 NIMH-NIDA-sponsored health economics conference, and the ideas presented there for developing and assessing innovative behavioral health care financing models; three of the presented papers were recently published in the Journal of Mental Health Policy and Economics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We describe the history and impact of NIMH- and NIDA-sponsored economic research and identify current research interests as identified in the NIMH and NIDA Strategic Plans and recent funding announcements. We examine themes presented at the NIMH-NIDA Health Economics conference. The conference included over 300 participants from 20 countries, from six continents.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The topics highlighted at the conference highlight the ways in which NIH-funded research has promoted the development of innovative health care financing methods, both from the supply side (e.g., providers and payers) and demand side (e.g., service users and families). Invited speakers discussed the findings from NIH-supported research in the topic areas of payment and financing, behavioral economics and social determinants of health. Keynote speakers highlighted emerging topics in the field, including the economics of health equity, biases in mental health models in health care, and value-based insurance design.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;We demonstrate a resurgence of and explicit interest in health economics and policy research at NIMH and NIDA. However, more work is needed in order to design funding mechanisms that fully provide access to and facilitate use of effective evidence-based practices to improve mental health outcomes. For example, it is important that policy and health economic research projects include decision makers who will be the end users of data and study results, to ensure that results can be meaningfully put into practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implications for health care: &lt;/strong&gt;Designing effective and efficient funding mechanisms can help ensure that service users have access to effective treatments and that clinicians and provider organizations are adequately compensated for their work.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implications for health policies: &lt;/strong&gt;Fe","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 1","pages":"33-39"},"PeriodicalIF":1.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PERSPECTIVE: A Path to Value-Based Insurance Design for Mental Health Services. PERSPECTIVE: A Path to Value-Based Insurance Design for Mental Health Services.
IF 1.6 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-03-01
Michael C Freed, Jennifer L Humensky, Patricia A Arean

Background: Aligning cost of mental health care with expected clinical and functional benefits of that care would incentivize the delivery of high value treatments and services. In turn, ineffective or untested care could still be offered but at costs high enough to offset the delivery of high value care.

Aims: The authors comment on Benson and Fendrick's paper on Value-Based Insurance Design (VBID) for mental health in the September 2023 special issue of this journal. The authors also present a preliminary framework of key ingredients needed to consider VBID for mental health treatments and services.

Methods: The authors briefly review current and past efforts to contain costs and improve quality of mental health care, which include (for example) use of carve-out and carve-in programs, evaluation of cost sharing models, impact of accountable care organizations, and studying other benefit designs and impact of federal and state policies.

Results: Using PTSD as an example, key ingredients of VBID for mental health services were identified and include the following: tools for case identification and monitoring progress over time at the population level; specific treatments and services with evidence of clinical effectiveness, cost-effectiveness, and health equity; and an approach to document the specific treatment or service was delivered (versus another treatment or service that may lack evidence).

Discussion: The inability to afford mental health care is a top barrier to treatment seeking. People who do elect to spend time and money on mental health care are further disadvantaged by accessing care that is not well regulated and the quality at best is questionable. VBID could be an important lever for increasing access to and use of high value mental health care. Partnerships among the research, practice, and policy communities can help ensure research solutions meet needs of these two communities.

Implications for health care: VBID holds promise to make high value mental health care more affordable while discouraging low value treatments and services.

Implications for health policies: While evidence gaps remain, these gaps can be filled concurrently with pursuit of VBID for mental health services.

Implications for future research: This paper identifies important research opportunities to help make VBID a reality for mental health care.

背景:将心理健康护理的成本与该护理的预期临床和功能效益挂钩,将激励提供高价值的治疗和服务。反过来,无效或未经测试的医疗服务仍可提供,但其成本足以抵消高价值医疗服务的提供。目的:作者对本森和芬德瑞克在本刊 2023 年 9 月特刊上发表的关于心理健康价值型保险设计(VBID)的论文进行了评论。作者还提出了一个初步框架,其中包含了考虑心理健康治疗和服务的 VBID 所需的关键要素:作者简要回顾了当前和过去为控制成本和提高精神卫生保健质量所做的努力,其中包括(例如)使用 "退出 "和 "加入 "计划、成本分担模式评估、责任医疗组织的影响、研究其他福利设计以及联邦和州政策的影响:结果:以创伤后应激障碍为例,确定了心理健康服务 VBID 的关键要素,其中包括以下内容:病例识别工具和在人群层面监测随时间推移的进展情况;具有临床有效性、成本效益和健康公平性证据的特定治疗和服务;记录特定治疗或服务提供情况的方法(相对于可能缺乏证据的其他治疗或服务):无力负担心理健康医疗费用是寻求治疗的首要障碍。而那些选择花费时间和金钱在心理健康护理上的人,则会因为获得的护理没有得到很好的监管,充其量也只是质量有问题的护理而处于更加不利的地位。VBID 可以成为增加获取和使用高价值心理健康护理的重要杠杆。研究、实践和政策团体之间的合作有助于确保研究解决方案满足这两个团体的需求:VBID 有望使高价值的心理健康护理更加经济实惠,同时抑制低价值的治疗和服务:对未来研究的启示:本文指出了重要的研究机会,以帮助实现心理健康服务的 VBID。
{"title":"PERSPECTIVE: A Path to Value-Based Insurance Design for Mental Health Services.","authors":"Michael C Freed, Jennifer L Humensky, Patricia A Arean","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Aligning cost of mental health care with expected clinical and functional benefits of that care would incentivize the delivery of high value treatments and services. In turn, ineffective or untested care could still be offered but at costs high enough to offset the delivery of high value care.</p><p><strong>Aims: </strong>The authors comment on Benson and Fendrick's paper on Value-Based Insurance Design (VBID) for mental health in the September 2023 special issue of this journal. The authors also present a preliminary framework of key ingredients needed to consider VBID for mental health treatments and services.</p><p><strong>Methods: </strong>The authors briefly review current and past efforts to contain costs and improve quality of mental health care, which include (for example) use of carve-out and carve-in programs, evaluation of cost sharing models, impact of accountable care organizations, and studying other benefit designs and impact of federal and state policies.</p><p><strong>Results: </strong>Using PTSD as an example, key ingredients of VBID for mental health services were identified and include the following: tools for case identification and monitoring progress over time at the population level; specific treatments and services with evidence of clinical effectiveness, cost-effectiveness, and health equity; and an approach to document the specific treatment or service was delivered (versus another treatment or service that may lack evidence).</p><p><strong>Discussion: </strong>The inability to afford mental health care is a top barrier to treatment seeking. People who do elect to spend time and money on mental health care are further disadvantaged by accessing care that is not well regulated and the quality at best is questionable. VBID could be an important lever for increasing access to and use of high value mental health care. Partnerships among the research, practice, and policy communities can help ensure research solutions meet needs of these two communities.</p><p><strong>Implications for health care: </strong>VBID holds promise to make high value mental health care more affordable while discouraging low value treatments and services.</p><p><strong>Implications for health policies: </strong>While evidence gaps remain, these gaps can be filled concurrently with pursuit of VBID for mental health services.</p><p><strong>Implications for future research: </strong>This paper identifies important research opportunities to help make VBID a reality for mental health care.</p>","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 1","pages":"23-31"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of Antidepressants in Combination with Psychotherapy. 抗抑郁药与心理疗法相结合的疗效。
IF 1.6 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-03-01
Farrokh Alemi, Tulay G Soylu, Mary Cannon, Conor McCandless
<p><strong>Background: </strong>Consensus-guidelines for prescribing antidepressants recommend that clinicians should be vigilant to match antidepressants to patient's medical history but provide no specific advice on which antidepressant is best for a given medical history.</p><p><strong>Aims of the study: </strong>For patients with major depression who are in psychotherapy, this study provides an empirically derived guideline for prescribing antidepressant medications that fit patients' medical history.</p><p><strong>Methods: </strong>This retrospective, observational, cohort study analyzed a large insurance database of 3,678,082 patients. Data was obtained from healthcare providers in the U.S. between January 1, 2001, and December 31, 2018. These patients had 10,221,145 episodes of antidepressant treatments. This study reports the remission rates for the 14 most commonly prescribed single antidepressants (amitriptyline, bupropion, citalopram, desvenlafaxine, doxepin, duloxetine, escitalopram, fluoxetine, mirtazapine, nortriptyline, paroxetine, sertraline, trazodone, and venlafaxine) and a category named "Other" (other antidepressants/combination of antidepressants). The study used robust LASSO regressions to identify factors that affected remission rate and clinicians' selection of antidepressants. The selection bias in observational data was removed through stratification. We organized the data into 16,770 subgroups, of at least 100 cases, using the combination of the largest factors that affected remission and selection bias. This paper reports on 2,467 subgroups of patients who had received psychotherapy.</p><p><strong>Results: </strong>We found large, and statistically significant, differences in remission rates within subgroups of patients. Remission rates for sertraline ranged from 4.5% to 77.86%, for fluoxetine from 2.86% to 77.78%, for venlafaxine from 5.07% to 76.44%, for bupropion from 0.5% to 64.63%, for desvenlafaxine from 1.59% to 75%, for duloxetine from 3.77% to 75%, for paroxetine from 6.48% to 68.79%, for escitalopram from 1.85% to 65%, and for citalopram from 4.67% to 76.23%. Clearly these medications are ideal for patients in some subgroups but not others. If patients are matched to the subgroups, clinicians can prescribe the medication that works best in the subgroup. Some medications (amitriptyline, doxepin, nortriptyline, and trazodone) always had remission rates below 11% and therefore were not suitable as single antidepressant therapy for any of the subgroups.</p><p><strong>Discussions: </strong>This study provides an opportunity for clinicians to identify an optimal antidepressant for their patients, before they engage in repeated trials of antidepressants.</p><p><strong>Implications for health care provision and use: </strong>To facilitate the matching of patients to the most effective antidepressants, this study provides access to a free, non-commercial, decision aid at http://MeAgainMeds.com.</p><p><strong>Implicati
背景:抗抑郁药物处方共识指南建议临床医生应根据患者的病史警惕性地选择抗抑郁药物,但并未就特定病史最适合哪种抗抑郁药物提供具体建议:研究目的:对于接受心理治疗的重度抑郁症患者,本研究为根据患者病史开具抗抑郁药物处方提供了经验性指导:这项回顾性、观察性、队列研究分析了一个包含 3,678,082 名患者的大型保险数据库。数据来自 2001 年 1 月 1 日至 2018 年 12 月 31 日期间美国的医疗服务提供者。这些患者共接受了 10,221,145 次抗抑郁治疗。本研究报告了14种最常处方的单一抗抑郁药(阿米替林、安非他酮、西酞普兰、去文拉法辛、多虑平、度洛西汀、艾司西酞普兰、氟西汀、米氮平、去甲替林、帕罗西汀、舍曲林、曲唑酮和文拉法辛)和一个名为 "其他 "的类别(其他抗抑郁药/抗抑郁药复方)的缓解率。研究采用稳健的LASSO回归法来确定影响缓解率和临床医生选择抗抑郁药物的因素。通过分层消除了观察性数据中的选择偏差。我们利用影响缓解率和选择偏差的最大因素组合,将数据分为 16,770 个至少有 100 个病例的亚组。本文报告了 2467 个接受过心理治疗的患者分组的情况:结果:我们发现,在亚组患者中,缓解率存在很大差异,而且在统计学上具有显著意义。舍曲林的缓解率从 4.5% 到 77.86%,氟西汀的缓解率从 2.86% 到 77.78%,文拉法辛的缓解率从 5.07% 到 76.44%,安非他酮的缓解率从 0.5% 到 64.63%,去文拉法辛从 1.59% 到 75%,度洛西汀从 3.77% 到 75%,帕罗西汀从 6.48% 到 68.79%,艾司西酞普兰从 1.85% 到 65%,西酞普兰从 4.67% 到 76.23%。显然,这些药物对某些亚组的患者来说是理想的选择,但对其他亚组的患者来说则不是。如果将患者与亚组相匹配,临床医生就可以为亚组患者开具疗效最好的药物。有些药物(阿米替林、多虑平、去甲替林和曲唑酮)的缓解率总是低于 11%,因此不适合作为任何亚组的单一抗抑郁治疗药物:讨论:这项研究为临床医生提供了一个机会,使他们能够在反复试验抗抑郁药之前,为患者确定最佳抗抑郁药:为便于将患者与最有效的抗抑郁药物相匹配,本研究提供了免费、非商业性的决策辅助工具,http://MeAgainMeds.com.Implications: 政策制定者应评估如何通过零散的医疗点电子健康记录提供研究结果。另外,政策制定者还可以建立一个人工智能系统,在家中向患者在线推荐抗抑郁药物,并鼓励他们在下次就诊时将推荐意见带给临床医生: 未来的研究可以调查(i)我们的建议在改变临床实践方面的有效性,(ii)提高抑郁症状的缓解率,以及(iii)降低护理成本。这些研究需要具有前瞻性,但要务实。随机临床试验不太可能解决影响缓解的大量因素。
{"title":"Effectiveness of Antidepressants in Combination with Psychotherapy.","authors":"Farrokh Alemi, Tulay G Soylu, Mary Cannon, Conor McCandless","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Consensus-guidelines for prescribing antidepressants recommend that clinicians should be vigilant to match antidepressants to patient's medical history but provide no specific advice on which antidepressant is best for a given medical history.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aims of the study: &lt;/strong&gt;For patients with major depression who are in psychotherapy, this study provides an empirically derived guideline for prescribing antidepressant medications that fit patients' medical history.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective, observational, cohort study analyzed a large insurance database of 3,678,082 patients. Data was obtained from healthcare providers in the U.S. between January 1, 2001, and December 31, 2018. These patients had 10,221,145 episodes of antidepressant treatments. This study reports the remission rates for the 14 most commonly prescribed single antidepressants (amitriptyline, bupropion, citalopram, desvenlafaxine, doxepin, duloxetine, escitalopram, fluoxetine, mirtazapine, nortriptyline, paroxetine, sertraline, trazodone, and venlafaxine) and a category named \"Other\" (other antidepressants/combination of antidepressants). The study used robust LASSO regressions to identify factors that affected remission rate and clinicians' selection of antidepressants. The selection bias in observational data was removed through stratification. We organized the data into 16,770 subgroups, of at least 100 cases, using the combination of the largest factors that affected remission and selection bias. This paper reports on 2,467 subgroups of patients who had received psychotherapy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We found large, and statistically significant, differences in remission rates within subgroups of patients. Remission rates for sertraline ranged from 4.5% to 77.86%, for fluoxetine from 2.86% to 77.78%, for venlafaxine from 5.07% to 76.44%, for bupropion from 0.5% to 64.63%, for desvenlafaxine from 1.59% to 75%, for duloxetine from 3.77% to 75%, for paroxetine from 6.48% to 68.79%, for escitalopram from 1.85% to 65%, and for citalopram from 4.67% to 76.23%. Clearly these medications are ideal for patients in some subgroups but not others. If patients are matched to the subgroups, clinicians can prescribe the medication that works best in the subgroup. Some medications (amitriptyline, doxepin, nortriptyline, and trazodone) always had remission rates below 11% and therefore were not suitable as single antidepressant therapy for any of the subgroups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussions: &lt;/strong&gt;This study provides an opportunity for clinicians to identify an optimal antidepressant for their patients, before they engage in repeated trials of antidepressants.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implications for health care provision and use: &lt;/strong&gt;To facilitate the matching of patients to the most effective antidepressants, this study provides access to a free, non-commercial, decision aid at http://MeAgainMeds.com.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Implicati","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 1","pages":"3-12"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Economic Burden of Chronic Psychotic Disorders: An Incidence-based Cost-of-Illness Approach. 慢性精神障碍的经济负担:基于发病率的疾病成本法》。
IF 1.6 4区 医学 Q4 HEALTH POLICY & SERVICES Pub Date : 2024-03-01
Claire de Oliveira, Bryan Tanner

Background: The economic burden of chronic psychotic disorders is substantial. However, few studies have employed an incidence based approach to estimate the economic burden of chronic psychotic disorders. Furthermore, the existing work has mainly used models populated with data obtained from published literature, making several assumptions to estimate incidence-based costs.

Aims of the study: The objective of this study was to estimate the direct cumulative mean health care costs of chronic psychotic disorders, using an incidence-based, cost-of-illness approach and real-world data from a single-payer health care system.

Methods: Using health records from Ontario, Canada, all individuals with a valid health card number, residing in the province, and diagnosed with a chronic psychotic disorder between the ages of 16 and 45 from April 1st, 2006, to March 31st, 2021, were included in the analysis. Using a mix of bottom-up and top-down methodologies and a robust cost estimator, cumulative mean health care costs were estimated from diagnosis to death or the end of observation period. Cumulative mean health care costs, and respective 95% confidence intervals (CIs), were estimated for the 1-year period (i.e., first year post-diagnosis), overall, by sex, age groups and health service, and for the 5-, 10- and 15-periods, overall and by sex.

Results: One-, 5-, 10- and 15-year total discounted cumulative mean health care costs were estimated at USD 24,441.16, 95% CI (USD 24,166.13, USD 24,716.19), USD 70,754.69, 95% CI (USD 69,827.48-USD 71,681.89), USD 117,136.88, 95% CI (USD 115,370.40-USD 118,903.35), and USD 157,829.01 95% CI (USD 155,599.32.-USD 160,058.70), respectively. Total mean 1-year costs post-diagnosis were higher for younger individuals. Although females had higher 1-year costs, males had higher 5-, 10- and 15-year costs. Psychiatric hospitalisations made up the largest component of total costs across all cost estimates.

Discussion: These results suggest that the costs of chronic psychotic disorders are high in the year of diagnosis and then increase at a decreasing rate thereafter. Compared to previous work, the cost estimates from the present study suggest that the use of real-world data produces lower estimates of cumulative costs, albeit likely more accurate ones. However, these estimates do not account for costs of care provided in community-based agencies.

Implications for health policies: These estimates will serve as important inputs for policymakers looking to make decisions around resource allocation.

Implications for future research: Future research should seek to follow incident cases in administrative data over a longer time period to obtain cumulative costs of longer duration.

背景:慢性精神障碍造成的经济负担十分沉重。然而,很少有研究采用基于发病率的方法来估算慢性精神病的经济负担。此外,现有研究主要使用从公开发表的文献中获取的数据建立模型,并做出若干假设来估算基于发病率的成本:本研究的目的是使用基于发病率的疾病成本法和来自单一付费医疗系统的真实世界数据,估算慢性精神病性障碍的直接累积平均医疗成本:方法:利用加拿大安大略省的健康记录,将 2006 年 4 月 1 日至 2021 年 3 月 31 日期间所有拥有有效健康卡号、居住在该省并被诊断出患有慢性精神病性障碍的 16 至 45 岁人群纳入分析范围。通过混合使用自下而上和自上而下的方法以及稳健的成本估算器,估算了从诊断到死亡或观察期结束的累计平均医疗成本。按性别、年龄组和医疗服务估算了1年期(即诊断后第一年)的总体累计平均医疗成本和各自的95%置信区间(CIs),并按性别估算了5、10和15年期的总体累计平均医疗成本和各自的95%置信区间(CIs):1年、5年、10年和15年的总贴现累计平均医疗费用估计分别为24,441.16美元(95% CI为24,166.13美元,24,716.19美元)、70,754.69美元(95% CI为70,754.69美元)、70,754.69美元(95% CI为70,754.69美元)和70,754.69美元(95% CI为70,754.69美元)。69美元(95% CI,69,827.48-71,681.89美元)、117,136.88美元(95% CI,115,370.40-118,903.35美元)和157,829.01美元(95% CI,155,599.32-160,058.70美元)。年轻患者确诊后 1 年的平均总费用较高。虽然女性的 1 年费用较高,但男性的 5 年、10 年和 15 年费用较高。在所有成本估算中,精神科住院治疗占总成本的最大部分:讨论:这些结果表明,慢性精神障碍的成本在确诊当年较高,之后以递减的速度增长。与之前的研究相比,本研究的成本估算结果表明,使用真实世界的数据得出的累积成本估算结果较低,尽管可能更为准确。然而,这些估算并未考虑社区机构提供的护理成本:对未来研究的启示:这些估算值将作为决策者在资源分配方面决策的重要依据:未来研究的启示:未来的研究应寻求在更长的时间段内跟踪行政数据中的事件病例,以获得持续时间更长的累积成本。
{"title":"The Economic Burden of Chronic Psychotic Disorders: An Incidence-based Cost-of-Illness Approach.","authors":"Claire de Oliveira, Bryan Tanner","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The economic burden of chronic psychotic disorders is substantial. However, few studies have employed an incidence based approach to estimate the economic burden of chronic psychotic disorders. Furthermore, the existing work has mainly used models populated with data obtained from published literature, making several assumptions to estimate incidence-based costs.</p><p><strong>Aims of the study: </strong>The objective of this study was to estimate the direct cumulative mean health care costs of chronic psychotic disorders, using an incidence-based, cost-of-illness approach and real-world data from a single-payer health care system.</p><p><strong>Methods: </strong>Using health records from Ontario, Canada, all individuals with a valid health card number, residing in the province, and diagnosed with a chronic psychotic disorder between the ages of 16 and 45 from April 1st, 2006, to March 31st, 2021, were included in the analysis. Using a mix of bottom-up and top-down methodologies and a robust cost estimator, cumulative mean health care costs were estimated from diagnosis to death or the end of observation period. Cumulative mean health care costs, and respective 95% confidence intervals (CIs), were estimated for the 1-year period (i.e., first year post-diagnosis), overall, by sex, age groups and health service, and for the 5-, 10- and 15-periods, overall and by sex.</p><p><strong>Results: </strong>One-, 5-, 10- and 15-year total discounted cumulative mean health care costs were estimated at USD 24,441.16, 95% CI (USD 24,166.13, USD 24,716.19), USD 70,754.69, 95% CI (USD 69,827.48-USD 71,681.89), USD 117,136.88, 95% CI (USD 115,370.40-USD 118,903.35), and USD 157,829.01 95% CI (USD 155,599.32.-USD 160,058.70), respectively. Total mean 1-year costs post-diagnosis were higher for younger individuals. Although females had higher 1-year costs, males had higher 5-, 10- and 15-year costs. Psychiatric hospitalisations made up the largest component of total costs across all cost estimates.</p><p><strong>Discussion: </strong>These results suggest that the costs of chronic psychotic disorders are high in the year of diagnosis and then increase at a decreasing rate thereafter. Compared to previous work, the cost estimates from the present study suggest that the use of real-world data produces lower estimates of cumulative costs, albeit likely more accurate ones. However, these estimates do not account for costs of care provided in community-based agencies.</p><p><strong>Implications for health policies: </strong>These estimates will serve as important inputs for policymakers looking to make decisions around resource allocation.</p><p><strong>Implications for future research: </strong>Future research should seek to follow incident cases in administrative data over a longer time period to obtain cumulative costs of longer duration.</p>","PeriodicalId":46381,"journal":{"name":"Journal of Mental Health Policy and Economics","volume":"27 1","pages":"13-21"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Mental Health Policy and Economics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1